According to a team of analysts at Barclays, the situation with the supply of COVID-19 vaccines in the European Union improved. Experts suggest that Europe will develop herd immunity against the deadly virus by this autumn.
A survey provided by Barclays shows that 70% of the European population will acquire immunity from COVID-19 by September of 2021. The investment bank assumes that the vaccine supply will grow exponentially to 360 million doses in the second quarter of the year. Notably, the drug supply did not exceed 98 million doses in the first quarter of 2021.
Around 10% of European citizens have already received their first Pfizer vaccine shot. According to Barclays experts’ estimates, by the end of the first quarter of 2021, Pfizer and AstraZeneca will deliver 59 million and 30 million doses of their vaccines to Europe respectively. Pfizer plans to provide the EU with additional 200 million doses in the second quarter of the year.
Immunization in the EU is expected to accelerate along with the pace of the vaccine rollout. Barclays also projects an increase in the supply of COVID-19 jabs. In 2021, the vaccine supply in the EU is estimated to reach 98 million doses in Q1, 360 million doses in Q2, 597 million doses in Q3, and 390 million in Q4.